Biotech Values

[dewophile]

just googling they had high SVRs in good prognosis gen-1 pts
the nulls did poorly as did hose with unfavorable il-28b polymorphisms hence the move to add a third drug
not sure if 1a vs 1b outcomes were reported but bottom line there is a significant slice of the gen-1 market that responds well to 2 drug combo with sofosbuvir